Youth Forum of APACC 2023  | (5R)-5-hydroxytriptolide Holds Promise for HIV immunological Non-responders Receiving ART

Youth Forum of APACC 2023  | (5R)-5-hydroxytriptolide Holds Promise for HIV immunological Non-responders Receiving ART

2023.10.23
Hello everyone, I'm Xiaosheng Liu , a graduate student from Professor Taisheng Li's team of Peking Union Medical College Hospital, China. My primary research focus is on the mechanisms underlying immunological non-response in HIV/AIDS patients after long-term antiviral therapy and the development of therapeutic drugs for this condition. I'm delighted to participate in this year's APACC conference (2023) and present two poster studies conducted by our team at the conference. APACC is the most cutting-edge and top academic conference in the Asia-Pacific region for HIV/AIDS, and I hope to broaden my knowledge in various aspects through this conference.
Dr. Jennifer Hoy: How to Safely Transition ART in HIV Patients Achieving Viral Suppression?

Dr. Jennifer Hoy: How to Safely Transition ART in HIV Patients Achieving Viral Suppression?

2023.10.22
Infectious Disease/HIV Specialist and Medical Professor at Monash University Alfred Hospital, Australia. Member of the Australian Antiretroviral Guidelines Committee and the International Antiviral Society-USA (IAS-USA) Antiretroviral Guidelines Panel. Leading and participating in the development of new antiretroviral drugs and the prevention and management of opportunistic infections, with a primary research focus on complications related to aging in HIV-infected individuals and their pathogenesis, prevention, and management.
Dr. Iskandar Azwa: Second and Third-Line Treatment Options for HIV/AIDS Patients

Dr. Iskandar Azwa: Second and Third-Line Treatment Options for HIV/AIDS Patients

2023.10.22
Chairman of the Malaysian AIDS Council, Head of Infectious Diseases Department at the University of Malaya Medical Center. His research interests include pre-exposure prophylaxis (PrEP) implementation in key populations, HIV drug resistance, and evaluating new HIV treatment strategies. He is the principal investigator for several international collaborative HIV clinical trials, including TAHOD, START, and D2EFT studies.
Dr. Hui Wang: Second-line treatment choice for children with HIV infection

Dr. Hui Wang: Second-line treatment choice for children with HIV infection

2023.10.12
Currently, the choice of second-line antiretroviral therapy (ART) for children infected with HIV is extremely limited. At the12th International AIDS Society HIV Science Conference (IAS 2023), researchers announced the results of a significant clinical study, the CHAPAS-4 ( Abstract No. OALBB0503), focusing on the long-term treatment outcomes of second-line therapy in children with HIV infections. We specially invited Dr. Hui Wang from the Affiliated Second Hospital of Southern University of Science and Technology, China, to provide a brilliant review of this research.